BMY

How is BMY doing right now?

In plain terms: BMY is 19.5% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.

Right now BMY — Bristol Myers Squibb — is in a moderate correction, down 19.5% from its record high. Last price: $55.92. Corrections in this band are common during macro repricings (rate scares, sector rotations, earnings shocks). The question is whether the cause is durable or transient.

What history says at this drawdown

Across all available history, BMY has spent enough trading days in the 20%-to-15% drawdown band to build a large sample (1110 observations). Dipsern segments these by drawdown depth and computes the rolling median forward 90-day return — that median is the primary signal you see in the full app, and it's substantially more robust than mean-based forecasts because it ignores fat-tail outliers in both directions.

What this means for BMY

For US large-caps, drawdowns of 20-30% are typically driven by macro repricing (rates, earnings, sector rotation). Single-name 50%+ drawdowns are usually structural — the signal alone won't tell you which, but the segments table will show whether prior episodes recovered. This is the band where most successful "buy the dip" strategies have historically operated. The median forward return here for BMY is in the full app, alongside the segment-level win rate.